Cervical Cancer Diagnostics Market Report by Test Type (Pap Testing, HPV Testing, Cervical Biopsies, Colposcopy, and Others), Age Group (20 to 35 Years, Above 35 Years), and Region 2024-2032

Cervical Cancer Diagnostics Market Report by Test Type (Pap Testing, HPV Testing, Cervical Biopsies, Colposcopy, and Others), Age Group (20 to 35 Years, Above 35 Years), and Region 2024-2032

The global cervical cancer diagnostics market size reached US$ 8.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.8% during 2024-2032.

Cervical cancer diagnostics rely on a series of advanced laboratory tests, tools and procedures to evaluate abnormal cells or strains of the human papillomavirus (HPV). They are performed by taking a sample of the tissue obtained through conization, punch biopsy, endocervical curettage and the electrical wire loop for a thorough examination of the cervix during colposcopy. After detection, tests like blood, chest X-ray, body computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan and visual examination of bladder and rectum are conducted to determine the disease stage.

A considerable rise in the number of individuals diagnosed with sexually transmitted infections (STIs), such as syphilis, chlamydia, gonorrhea and acquired immune deficiency syndrome (HIV/AIDS), is escalating the risk of HPV infection worldwide. This, along with the growing number of smokers, which increases the chances of developing cervical cancer, represents one of the key factors bolstering the market growth. Furthermore, the rising awareness about early diagnosis is encouraging the adoption of HPV home testing kits that provide quick and accurate test results. The presence of favorable reimbursement policies also supports the market growth. Apart from this, rising preferences for personalized treatment plans are escalating the demand for cervical cancer diagnostics. Additionally, the availability of a range of other treatment options, including surgery, radiation therapy, chemotherapy, cone biopsy, immunotherapy and trachelectomy, is contributing to the market growth. Moreover, the growing emphasis on developing low-cost and efficient testing products is anticipated to fuel the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cervical cancer diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type and age group.

Breakup by Test Type:

• Pap Testing
• HPV Testing
• Cervical Biopsies
• Colposcopy
• Others

Breakup by Age Group:

• 20 to 35 years
• Above 35 years

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company, Cooper Surgical Inc., F. Hoffmann-La Roche AG, Guided Therapeutics Inc., Hologic Inc., Qiagen, Quest Diagnostics Incorporated and Siemens Healthcare GmbH.

Key Questions Answered in This Report

1. How big is the global cervical cancer diagnostics market?

2. What is the expected growth rate of the global cervical cancer diagnostics market during 2024-2032?

3. What are the key factors driving the global cervical cancer diagnostics market?

4. What has been the impact of COVID-19 on the global cervical cancer diagnostics market?

5. What is the breakup of the global cervical cancer diagnostics market based on the test type?

6. What are the key regions in the global cervical cancer diagnostics market?

7. Who are the key players/companies in the global cervical cancer diagnostics market?